Inogen (NASDAQ:INGN) Earns Hold Rating from Needham & Company LLC

Inogen (NASDAQ:INGN)‘s stock had its “hold” rating reissued by investment analysts at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports.

Separately, StockNews.com downgraded shares of Inogen from a “buy” rating to a “hold” rating in a report on Friday, December 20th.

Inogen Trading Up 2.4 %

INGN opened at $10.88 on Tuesday. The business has a 50 day moving average of $9.52 and a 200-day moving average of $9.90. The stock has a market capitalization of $259.14 million, a price-to-earnings ratio of -4.84 and a beta of 1.02. Inogen has a 1-year low of $5.08 and a 1-year high of $13.33.

Institutional Trading of Inogen

A number of hedge funds have recently modified their holdings of the company. Divisadero Street Capital Management LP raised its stake in shares of Inogen by 682.3% in the second quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company’s stock valued at $19,079,000 after purchasing an additional 2,046,766 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Inogen by 312.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock valued at $1,694,000 after buying an additional 132,287 shares during the period. AQR Capital Management LLC raised its stake in shares of Inogen by 29.3% in the 2nd quarter. AQR Capital Management LLC now owns 570,994 shares of the medical technology company’s stock valued at $4,642,000 after buying an additional 129,307 shares in the last quarter. Sanctuary Advisors LLC bought a new position in shares of Inogen during the 2nd quarter worth about $651,000. Finally, B. Riley Wealth Advisors Inc. bought a new position in shares of Inogen during the 2nd quarter worth about $457,000. Institutional investors own 89.94% of the company’s stock.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.